Clinical Trial Search

Primary: Number of Participants With Clinical Response at Week 6 — 60; 108; 116 participants — p=< 0.001

Primary: Seroprotection, Non-Atopic Dermatitis (AD), Intradermal vs. Moderate to Severe Atopic Dermatitis, Intradermal - Influenza B — 34.4; 22.5 percentage of participants…

Primary: Number of Participants With Peanut Allergy (PA) at 72 Months of Age - by Skin Prick Test Stratum — 34; 7; 18; 6 Participants — p=<0.001

Primary: Vaccine Pneumococcal Serotype Antibody Concentrations — 0.14; 0.38; 0.16; 1.35 μg/mL

Primary: Proportion of Subjects With Adverse Events (AEs) That Required Study Drug Discontinuation or Could Not be Controlled With Concomitant Medication — 2; 0; 2; 0 Participants

Primary: Number of Subjects With Solicited Local Symptoms — 20; 6; 1; 1 Subjects

Primary: Percentage of Participants With Local (Injection Site) Adverse Events (AEs) After Either Vaccine Dose by Maximum Severity as Assessed by the Clinical Staff — 16.7; 11.8…

Primary: Progression Free Survival Rate at 6 Months — 56 percentage of participants

Primary: Time Until Proper Endotracheal Tube Placement — 49; 64 seconds

Primary: Overall Response Rate — 0.0 proportion of participants

Primary: Proportion of Subjects Who Require Resumption of ART Between the Interruption of ART at Week 28 and End of Study at Week 52. — 88; 40; 88; 38 participants

Primary: Minimum Plasma Concentration (Cmin) of Simeprevir (SMV) — 2411; 6701 nanogram per Milliliters (ng/mL)

Primary: Alcohol Use as Assessed by Ethyl Glucuronide Detection in Urine — 408.86; 734.79 EtG Value (nanograms per milileter)

Primary: Time Infiltration Detected by Nurse — 29.8; 32.3 hours

Primary: Median Progression Free Survival (PFS) — 19.35; 14.85 Months — p=0.0014